Silo Pharma rises on licensing deal for Alzheimer's drug
16/07/2024 12:10
** Shares of Silo Pharma SILO.O gain 64.5% to $1.76
premarket
** Co enters into a global exclusive licensing agreement to
further develop, manufacture and commercialize Alzheimer's drug
SPC-14
** In April, SILO said it was set to acquire exclusive
licensing for SPC-14 from Columbia University
** Up to last close, stock down 25.7% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement